L.C.E. SANDOZ 100/25/200 levodopa 100 mg, carbidopa (as carbidopa monohydrate) 25 mg and entacapone 200 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 100/25/200 levodopa 100 mg, carbidopa (as carbidopa monohydrate) 25 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: povidone; iron oxide yellow; croscarmellose sodium; mannitol; glycerol; maize starch; titanium dioxide; magnesium stearate; polysorbate 80; hypromellose; sucrose; iron oxide red - l.c.e. sandoz 100/25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 75/18.75/200 levodopa 75 mg, carbidopa (as carbidopa monohydrate) 18.75 mg and entacapone 200 mg film-coated tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 75/18.75/200 levodopa 75 mg, carbidopa (as carbidopa monohydrate) 18.75 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg; levodopa, quantity: 75 mg - tablet, film coated - excipient ingredients: polysorbate 80; maize starch; hypromellose; croscarmellose sodium; iron oxide red; titanium dioxide; povidone; magnesium stearate; glycerol; mannitol; sucrose - l.c.e. sandoz 75/18.75/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

ENTACAPONE COMBI ACTAVIS 50/12.5/200 levodopa/carbidopa/entacapone 50/12.5/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

entacapone combi actavis 50/12.5/200 levodopa/carbidopa/entacapone 50/12.5/200 mg tablet bottle

medis pharma pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; powdered cellulose; sodium sulfate; trehalose dihydrate; magnesium stearate; carmellose sodium; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

ENTACAPONE COMBI ACTAVIS 150/37.5/200 levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

entacapone combi actavis 150/37.5/200 levodopa/carbidopa/entacapone 150/37.5/200 mg tablet bottle

medis pharma pty ltd - levodopa, quantity: 150 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; powdered cellulose; sodium sulfate; trehalose dihydrate; magnesium stearate; carmellose sodium; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Levodopa/Carbidopa/Entacapone Orion European Union - English - EMA (European Medicines Agency)

levodopa/carbidopa/entacapone orion

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - nervous system - levodopa/carbidopa/entacapone orion is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.

CARLEVENT levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 75/18.75/200 mg tablet bottle

medis pharma pty ltd - levodopa, quantity: 75 mg; carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: sodium sulfate; hyprolose; carmellose sodium; microcrystalline cellulose; magnesium stearate; trehalose dihydrate; powdered cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CARLEVENT levodopa/carbidopa/entacapone 200/50/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

carlevent levodopa/carbidopa/entacapone 200/50/200 mg tablet bottle

medis pharma pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: powdered cellulose; microcrystalline cellulose; sodium sulfate; carmellose sodium; magnesium stearate; hyprolose; trehalose dihydrate; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CENTEVO levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

centevo levodopa/carbidopa/entacapone 50 mg/12.5 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

CENTEVO levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

centevo levodopa/carbidopa/entacapone 150 mg/37.5 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 150 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; polysorbate 80; iron oxide red; carmoisine aluminium lake - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

KINSON levodopa 100 mg with carbidopa (as monohydrate) 25 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

kinson levodopa 100 mg with carbidopa (as monohydrate) 25 mg tablet bottle

alphapharm pty ltd - carbidopa monohydrate, quantity: 26.9 mg; levodopa, quantity: 100 mg - tablet, uncoated - excipient ingredients: povidone; purified talc; sodium starch glycollate; microcrystalline cellulose; quinoline yellow aluminium lake; maize starch; magnesium stearate - treatment of parkinson's disease and syndrome. it is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia. levodopa/carbidopa is frequently helpful in the management of tremor, dysphagia, sialorrhoea, and postural instability associated with parkinson's disease and syndrome.